Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PASG logo PASG
Upturn stock ratingUpturn stock rating
PASG logo

Passage Bio Inc (PASG)

Upturn stock ratingUpturn stock rating
$6.9
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: PASG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $59.25

1 Year Target Price $59.25

Analysts Price Target For last 52 week
$59.25 Target price
52w Low $5.12
Current$6.9
52w High $26.6

Analysis of Past Performance

Type Stock
Historic Profit -32.75%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 22.38M USD
Price to earnings Ratio 0.18
1Y Target Price 59.25
Price to earnings Ratio 0.18
1Y Target Price 59.25
Volume (30-day avg) 5
Beta 1.81
52 Weeks Range 5.12 - 26.60
Updated Date 08/28/2025
52 Weeks Range 5.12 - 26.60
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) 39.4

Earnings Date

Report Date 2025-07-31
When -
Estimate -0.202
Actual -2.96

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -33.2%
Return on Equity (TTM) -88.27%

Valuation

Trailing PE 0.18
Forward PE -
Enterprise Value -10516882
Price to Sales(TTM) -
Enterprise Value -10516882
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.87
Shares Outstanding 3178710
Shares Floating 2867165
Shares Outstanding 3178710
Shares Floating 2867165
Percent Insiders 0.21
Percent Institutions 54.51

ai summary icon Upturn AI SWOT

Passage Bio Inc

stock logo

Company Overview

overview logo History and Background

Passage Bio, Inc. (PASG) was founded in 2017 and focused on developing gene therapies for central nervous system disorders. It faced challenges and ultimately underwent a strategic restructuring and reverse merger.

business area logo Core Business Areas

  • Gene Therapy Development (Historical): Passage Bio previously focused on developing AAV-delivered gene therapies for rare, monogenic CNS diseases. This was the core of their operations before restructuring.
  • Transferred Technology Assets: In 2023, Passage Bio divested a majority of its pre-clinical AAV-based gene therapy technology assets and related personnel and infrastructure to a new private biotechnology company called Synnovation Bio.

leadership logo Leadership and Structure

Prior to its restructuring, Passage Bio had a typical biotech leadership team (CEO, CSO, etc.). Following the reverse merger, the leadership reflects that of the acquiring company.

Top Products and Market Share

overview logo Key Offerings

  • PBGM01 (historical): An AAV-delivered gene therapy for GM1 gangliosidosis. Development has been discontinued following their restructuring. Market share: Not applicable. Competitors: Before the discontinuation, competitors included companies developing similar gene therapies for lysosomal storage disorders.

Market Dynamics

industry overview logo Industry Overview

The gene therapy market is highly competitive and rapidly evolving. It involves significant regulatory hurdles and substantial investment in R&D. It now focuses on cell therapies, and biologics for treating chronic diseases. The industry is marked by high risk and potential high reward.

Positioning

Passage Bio, post-restructuring, now operates in a different capacity, primarily focused on managing its remaining assets and exploring new opportunities following the reverse merger. Their previous positioning as a gene therapy developer is no longer accurate.

Total Addressable Market (TAM)

The total addressable market for gene therapies addressing rare CNS disorders was estimated in the billions of dollars. Passage Bio's position relative to that TAM is now significantly reduced given the terminated programs and the reverse merger.

Upturn SWOT Analysis

Strengths

  • Cash reserves from previous funding rounds
  • Experienced management team during previous operations
  • Intellectual property related to AAV gene therapy (now transferred)

Weaknesses

  • Discontinued development programs
  • Lack of revenue-generating products
  • Uncertainty about future strategic direction
  • Negative publicity from restructuring

Opportunities

  • Strategic partnerships or acquisitions
  • Repurposing existing assets
  • Entering new therapeutic areas

Threats

  • Competition from established biotech companies
  • Regulatory hurdles for gene therapies
  • Financial instability
  • Market volatility
  • Uncertainty about regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • BLUE
  • AVRO
  • SGMO

Competitive Landscape

Passage Bio's competitive position was weakened by the discontinued programs. The merged entity now faces a new competitive landscape depending on its chosen area of focus.

Growth Trajectory and Initiatives

Historical Growth: Prior to the restructuring, Passage Bio experienced growth in terms of research and development spending, clinical trials initiation, and headcount. This growth has ceased.

Future Projections: Future projections are speculative and depend on the new direction of the merged entity.

Recent Initiatives: The most significant recent initiative was the strategic restructuring, the technology transfer to Synnovation Bio, and reverse merger to a new target

Summary

Passage Bio faced significant challenges, leading to a strategic restructuring, the divestiture of its gene therapy technology assets, and a reverse merger. Its previous business model focused on gene therapies for rare CNS disorders but its programs were discontinued. The company's future depends on the strategic direction of the new entity formed from the reverse merger. Investors should carefully evaluate any new business plans and assess the associated risks and opportunities.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Press Releases
  • Analyst Reports (historical)
  • Market Research Reports (historical)

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. The financial data and analysis are based on publicly available information and may not be entirely accurate or complete. Investing in biotech companies involves significant risks, including the risk of loss of capital.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Passage Bio Inc

Exchange NASDAQ
Headquaters Philadelphia, PA, United States
IPO Launch date 2020-02-28
President, CEO & Director Dr. William Chou M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 60
Full time employees 60

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.